Findings

What do systematic reviews say?

1,337 questions · 1,354 findings · 566 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 307 · 22.7%GRADE not reported 81 · 6%Very low 424 · 31.3%Low 310 · 22.9%Moderate 189 · 14%High 43 · 3.2%

Hypothermic oxygenated perfusion (HOPE) vs static cold storage (SCS)

Adverse events considered non‐serious · liver transplant recipients

1 finding from 1 review

Machine perfusion in liver transplantation 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 312 participants
GRADE not reported

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

Serious adverse events ‐ not reported · systemic lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

Serious adverse events ‐ not reported · systemic lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

Serious adverse events ‐ not reported · systemic lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Comprehensive geriatric assessment (CGA) vs usual care

Serious adverse events (falls) Median · older people at risk of poor health outcomes

It is very uncertain whether comprehensive Geriatric Assessment changes serious adverse events (falls) Median compared with usual care (very low certainty).

1 finding from 1 review

Comprehensive Geriatric Assessment for community‐dwelling, high‐risk, frail, older people 2022 · Cochrane Headline outcomes only
RR 0.82 [0.58, 1.17]
2 studies · 1380 participants
Very low

Summary of findings table ‐ Methylprednisolone vs dexamethasone

Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Band ligation vs no intervention or a sham procedure

Adverse events considered non‐serious · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment

The review found no eligible studies for this question.

1 finding from 1 review

Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

A functional programme vs a stretching programme

Adverse events/serious adverse events · people with NMD

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for promoting physical activity in people with neuromuscular disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

A physical activity programme (weight‐bearing) vs no physical activity

Adverse events/serious adverse events · people with NMD

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for promoting physical activity in people with neuromuscular disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

A sensor‐based, interactive exercise programme vs no sensor‐based, interactive exercise programme

Adverse events/serious adverse events · people with NMD

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for promoting physical activity in people with neuromuscular disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine vs placebo or usual care

Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease

1 finding from 1 review

Colchicine for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 4412 participants
Moderate

Methadone vs buprenorphine

Proportion of mothers with serious adverse events ( · opiate‐dependent pregnant women

Methadone showed no clear difference in serious adverse events for the mother compared with buprenorphine (low certainty).

1 finding from 1 review

Maintenance agonist treatments for opiate‐dependent pregnant women 2020 · Cochrane Headline outcomes only
RR 1.69 [0.75, 3.83]
1 study · 175 participants
Low

Physical activity advice plus placebo vs no physical activity advice plus placebo

Serious adverse events ‐ not reported · participants with quiescent IBD

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Physical activity advice plus placebo vs no physical activity advice plus omega 3

Serious adverse events ‐ not reported · participants with quiescent IBD

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.85 [0.74, 0.97]
1 study · 516 participants
Low

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.92 [0.78, 1.09]
1 study · 366 participants
Very low

Sunitinib vs everolimus (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with everolimus (targeted agent versus targeted agent) (moderate certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 1.34 [1.14, 1.59]
1 study · 469 participants
Moderate

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 1.01 [0.93, 1.1]
1 study · 873 participants
Low

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.9 [0.81, 1.02]
1 study · 854 participants
Low